<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04826406</url>
  </required_header>
  <id_info>
    <org_study_id>SHR-1210-IIT-HCC</org_study_id>
    <nct_id>NCT04826406</nct_id>
  </id_info>
  <brief_title>A Study of Camrelizumab Combined Apatinib in Hepatocellular Carcinoma Previously Treated With Immune Checkpoint Inhibitors (ICIs).</brief_title>
  <official_title>Camrelizumab Combined Apatinib in Patients With Hepatocellular Carcinoma Previously Treated With Immune Checkpoint Inhibitors: A Single-Arm, Open-Label, Phase II Study.</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Hunan Cancer Hospital</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Jiangsu Hengrui Pharmaceuticals Co.,Ltd</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>Hunan Cancer Hospital</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this study is to observe and preliminary explore the efficacy and safety of&#xD;
      the combination of Camrelizumab and Apatinib regimen in treating advanced hepatocellular&#xD;
      carcinoma (HCC) participants who have progressed following prior Immune Checkpoint Inhibitors&#xD;
      (ICIs) treatment.&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">February 3, 2021</start_date>
  <completion_date type="Anticipated">August 30, 2023</completion_date>
  <primary_completion_date type="Anticipated">March 2, 2022</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>N/A</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Objective Response Rate (ORR)</measure>
    <time_frame>Up to approximately 12 months</time_frame>
    <description>Objective Response Rate (ORR) per Response Evaluation Criteria in Solid Tumors Version 1.1 (RECIST 1.1).</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Progression-free survival(PFS)</measure>
    <time_frame>Up to approximately 12 months</time_frame>
    <description>Progression-free survival(PFS) per Response Evaluation Criteria in Solid Tumors Version 1.1 (RECIST 1.1).</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Time to objective response(TTR)</measure>
    <time_frame>Up to approximately 12 months</time_frame>
    <description>Time to objective response(TTR) per Response Evaluation Criteria in Solid Tumors Version 1.1 (RECIST 1.1)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Duration of Response (DoR)</measure>
    <time_frame>Up to approximately 12 months</time_frame>
    <description>Duration of Response (DoR) per Response Evaluation Criteria in Solid Tumors Version 1.1 (RECIST 1.1).</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Disease Control Rate (DCR)</measure>
    <time_frame>Up to approximately 12 months</time_frame>
    <description>Disease Control Rate (DCR) per Response Evaluation Criteria in Solid Tumors Version 1.1 (RECIST 1.1).</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>6-month survival rate</measure>
    <time_frame>Up to approximately 12 months</time_frame>
    <description>6-month survival rate</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>9-month survival rate</measure>
    <time_frame>Up to approximately 12 months</time_frame>
    <description>9-month survival rate</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>12-month survival rate</measure>
    <time_frame>Up to approximately 12 months</time_frame>
    <description>12-month survival rate</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Overall survival(OS)</measure>
    <time_frame>Up to approximately 24 months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Safety as measured by the rate of AEs, SAEs and laboratory abnormalities</measure>
    <time_frame>From the first assignment of informed consent form up to 90 days after the last dose</time_frame>
    <description>Safety as measured by the rate of AEs, SAEs and laboratory abnormalities (e.g. Grade 3 or higher per CTCAE v4 )</description>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Anticipated">40</enrollment>
  <condition>Hepatocellular Carcinoma</condition>
  <condition>Immune Checkpoint Inhibitors</condition>
  <arm_group>
    <arm_group_label>Camrelizumab+Apatinib</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Camrelizumab combined Apatinib regimen</intervention_name>
    <description>Camrelizumab 200mg iv every 2 weeks; Apatinib,250 mg/day.</description>
    <arm_group_label>Camrelizumab+Apatinib</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Aged 18 years old, both genders.&#xD;
&#xD;
          -  Conform to the clinical diagnosis histological or cytological confirmation of&#xD;
             HCC(hepatocellular carcinoma) and with at least one measurable lesion by computed&#xD;
             tomography (CT) scan or magnetic resonance imaging (MRI) according to RECIST 1.1.&#xD;
&#xD;
          -  Liver function status Child-Pugh score less than or equal to 7.&#xD;
&#xD;
          -  Barcelona Clinic Liver Cancer stage Category B or C.&#xD;
&#xD;
          -  Disease progression following prior Immune Checkpoint Inhibitors (PD-1/PD-L1 or CTLA4&#xD;
             inhibitors) treatment for HCC, for at least 2 consecutive treatment cycles. Receipt of&#xD;
             no more than 2 prior systemic therapies for advanced HCC.&#xD;
&#xD;
          -  Eastern Cooperative Oncology Group Performance Status of 0 or 1.&#xD;
&#xD;
          -  Life expectancy of at least 12 weeks.&#xD;
&#xD;
          -  Adequate bone marrow, liver and renal function (without blood transfusion, without&#xD;
             growth factor or blood components support within 14 days before enrollment).&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Patients with any active autoimmune disease or history of autoimmune disease,&#xD;
             including but not limited to the following: hepatitis, pneumonitis, uveitis, colitis&#xD;
             (inflammatory bowel disease), hypophysitis, vasculitis, nephritis, hyperthyroidism,&#xD;
             and hypothyroidism, except for subjects with vitiligo or resolved childhood&#xD;
             asthma/atopy. Asthma that requires intermittent use of bronchodilators or other&#xD;
             medical intervention should also be excluded.&#xD;
&#xD;
          -  The prior ICIs treatments were discontinued by intolerable adverse events.&#xD;
&#xD;
          -  Known or occurrence of central nervous system (CNS) metastases or hepatic&#xD;
             encephalopathy.&#xD;
&#xD;
          -  Patients with tumor burden ≥50% of the liver volume or received liver transplantation.&#xD;
&#xD;
          -  Patients with clinical symptoms of ascites.&#xD;
&#xD;
          -  Hypertension and unable to be controlled within normal level following treatment of&#xD;
             anti-hypertension agents(within 3 months): systolic blood pressure &gt; 140 mmHg,&#xD;
             diastolic blood pressure &gt; 90 mmHg.&#xD;
&#xD;
          -  Clinically significant cardiovascular and cerebrovascular diseases, including but not&#xD;
             limited to severe acute myocardial infarction within 6 months before enrollment,&#xD;
             unstable or severe angina, or coronary artery bypass surgery, Congestive heart failure&#xD;
             (New York heart association (NYHA) class &gt; 2), ventricular arrhythmia which need&#xD;
             medical intervention.&#xD;
&#xD;
          -  previous digestive tract bleeding history within 3 months or evident gastrointestinal&#xD;
             bleeding tendency, such as: esophageal varices, local active ulcerative lesions,&#xD;
             gastric ulcer and duodenal ulcer, the ulcerous colitis, gastrointestinal diseases such&#xD;
             as portal hypertension or resection of tumor with bleeding risk, etc.&#xD;
&#xD;
          -  Proteinuria ≥ (++) and 24 hours total urine protein &gt; 1.0 g.&#xD;
&#xD;
          -  Prior systemic chemotherapy, radiotherapy, immunotherapy, hormone therapy, surgery or&#xD;
             target therapy within 4 weeks (or 5 half-life of the drug, calculate the longer )&#xD;
             before the study drug administration, or any unresolved AEs &gt; Common Terminology&#xD;
             Criteria for Adverse Events (CTCAE) Grade 1.&#xD;
&#xD;
          -  Prior Camrelizumab or Apatinib treatments.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_contact>
    <last_name>Shanzhi Gu, MD</last_name>
    <phone>+86-731-88651900</phone>
    <email>gushanzhi@hnca.org.cn</email>
  </overall_contact>
  <location>
    <facility>
      <name>Hunan Cancer Hospital</name>
      <address>
        <city>Changsha</city>
        <state>Hunan</state>
        <zip>410013</zip>
        <country>China</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Shaozhi Gu, MD</last_name>
      <email>gushanzhi@hnca.org.cn</email>
    </contact>
    <investigator>
      <last_name>Shaozhi Gu, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>China</country>
  </location_countries>
  <verification_date>March 2021</verification_date>
  <study_first_submitted>March 29, 2021</study_first_submitted>
  <study_first_submitted_qc>March 29, 2021</study_first_submitted_qc>
  <study_first_posted type="Actual">April 1, 2021</study_first_posted>
  <last_update_submitted>March 29, 2021</last_update_submitted>
  <last_update_submitted_qc>March 29, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">April 1, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Carcinoma</mesh_term>
    <mesh_term>Carcinoma, Hepatocellular</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Apatinib</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>Undecided</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

